Cargando…

Soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice

OBJECTIVE: Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) most often caused by de novo pathogenic variants in SCN1A. Individuals with Dravet syndrome rarely achieve seizure control and have significantly elevated risk for sudden unexplained death in epilepsy (SUDEP). He...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hawkins, Nicole A., Jurado, Manuel, Thaxton, Tyler T., Duarte, Samantha E., Barse, Levi, Tatsukawa, Tetsuya, Yamakawa, Kazuhiro, Nishi, Toshiya, Kondo, Shinichi, Miyamoto, Maki, Abrahams, Brett S., During, Matthew J., Kearney, Jennifer A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Full‐length Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291096/ https://www.ncbi.nlm.nih.gov/pubmed/34510432 http://dx.doi.org/10.1111/epi.17062

Ejemplares similares

Anticonvulsive properties of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor
por: Nishi, Toshiya, et al.
Publicado: (2022)

Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice
por: Nishi, Toshiya, et al.
Publicado: (2020)

Gabra2 is a genetic modifier of Dravet syndrome in mice
por: Hawkins, Nicole A., et al.
Publicado: (2021)

Population pharmacokinetics, enzyme occupancy, and 24S‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults
por: Yin, Wei, et al.
Publicado: (2023)

Clinical Characterization of [(18)F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy
por: Constantinescu, Cristian C., et al.
Publicado: (2023)

The synthetic neuroactive steroid SGE-516 reduces seizure burden and improves survival in a Dravet syndrome mouse model
por: Hawkins, Nicole A., et al.
Publicado: (2017)

A phase 2, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox–Gastaut syndrome (ELEKTRA)
por: Hahn, Cecil D., et al.
Publicado: (2022)

Fenfluramine: New Treatment for Seizures in Dravet Syndrome
por: Pierce, Joanna Garcia, et al.
Publicado: (2020)

Heterozygous deletion of Gpr55 does not affect a hyperthermia-induced seizure, spontaneous seizures or survival in the Scn1a(+/)(-) mouse model of Dravet syndrome
por: Anderson, Lyndsey L., et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
por: Wang, Shining, et al.
Publicado: (2022)

Augmented Reticular Thalamic Bursting and Seizures in Scn1a-Dravet Syndrome
por: Ritter-Makinson, Stefanie, et al.
Publicado: (2019)

Augmented Reticular Thalamic Bursting and Seizures in Scn1a-Dravet Syndrome
por: Ritter-Makinson, Stefanie, et al.
Publicado: (2019)

Seizure reduction with fluoxetine in an adult woman with Dravet syndrome
por: Meador, Kimford J.
Publicado: (2014)

Nav1.1 haploinsufficiency in excitatory neurons ameliorates seizure-associated sudden death in a mouse model of Dravet syndrome
por: Ogiwara, Ikuo, et al.
Publicado: (2013)

Defining Dravet syndrome: An essential pre‐requisite for precision medicine trials
por: Li, Wenhui, et al.
Publicado: (2021)

Seizure control in a patient with Dravet syndrome and cystic fibrosis()
por: Schmalbach, Barbara, et al.
Publicado: (2013)

Unexpected Efficacy of a Novel Sodium Channel Modulator in Dravet Syndrome
por: Anderson, Lyndsey L., et al.
Publicado: (2017)

Perampanel Reduces Hyperthermia-Induced Seizures in Dravet Syndrome Mouse Model
por: Ho, Shih-Yin, et al.
Publicado: (2021)

A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication
por: Strzelczyk, Adam, et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
por: Wang, Shining, et al.
Publicado: (2021)

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
por: Devinsky, Orrin, et al.
Publicado: (2018)

A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway
por: Heger, Katrine, et al.
Publicado: (2020)

Autism spectrum disorder and cognitive profile in children with Dravet syndrome: Delineation of a specific phenotype
por: Ouss, Lisa, et al.
Publicado: (2018)

Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening
por: Griffin, Aliesha, et al.
Publicado: (2018)

Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome
por: Wong, Jennifer C., et al.
Publicado: (2019)

Selective Na(V)1.1 activation rescues Dravet syndrome mice from seizures and premature death
por: Richards, Kay L., et al.
Publicado: (2018)

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
por: Madan Cohen, Jennifer, et al.
Publicado: (2021)

Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program
por: Pernici, Chelsea D., et al.
Publicado: (2021)

High FGF‐21 level in a cohort of 22 patients with Dravet Syndrome—Possible relationship with the disease outcomes
por: Kwong, Anna Ka‐Yee, et al.
Publicado: (2021)

Dravet syndrome
por: Incorpora, Gemma
Publicado: (2009)

Randomized controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in adults with complex regional pain syndrome
por: Ratcliffe, Stuart, et al.
Publicado: (2022)

Heat-induced seizures, premature mortality, and hyperactivity in a novel Scn1a nonsense model for Dravet syndrome
por: Mavashov, Anat, et al.
Publicado: (2023)

Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study
por: Lai, Wyman W., et al.
Publicado: (2020)

Fine mapping and candidate gene analysis of a dravet syndrome modifier locus on mouse chromosome 11
por: Kearney, Jennifer A., et al.
Publicado: (2022)

Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq
por: Hawkins, Nicole A., et al.
Publicado: (2016)

Anti-Seizure Activity of 1-Adamantane Carboxylic Acid in Common Experimental Seizure Models: Role of Benzodiazepine-GABA(A) Receptors
por: Ghanbari, Elham, et al.
Publicado: (2021)

Sleep slow-wave oscillations trigger seizures in a genetic epilepsy model of Dravet syndrome
por: Catron, Mackenzie A, et al.
Publicado: (2022)

Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase
por: Koike, Tatsuki, et al.
Publicado: (2021)

Exploring linker's sequence diversity to fuse carotene cyclase and hydroxylase for zeaxanthin biosynthesis
por: Bouin, Aurélie, et al.
Publicado: (2023)

Determining the Relationship Between Seizure-Free Days and Other Predictors of Quality of Life in Patients with Dravet Syndrome and Their Carers from FFA Registration Studies
por: Pinsent, Amy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t4ovmnbh069jdh4m0h4c1evlc0